# BAD

## Overview
The BAD gene encodes the BCL2 associated agonist of cell death, a pro-apoptotic protein that is a member of the BCL-2 family. This protein is categorized as a 'BH3 domain only' protein, which plays a pivotal role in the regulation of apoptosis, a form of programmed cell death crucial for maintaining cellular homeostasis. The BAD protein promotes apoptosis by binding to and inhibiting anti-apoptotic proteins such as BCL-2 and BCL-XL, thereby facilitating the release of cytochrome c from mitochondria and triggering cell death pathways (Tan2000BAD; Reed2000Mechanisms). The activity of BAD is tightly regulated through phosphorylation, which modulates its interactions and subcellular localization, thus controlling its pro-apoptotic function (Cory2002The; Zha1996Serine). Dysregulation of BAD, through mutations or altered interactions, has significant implications in diseases such as cancer, where it can affect apoptosis signaling pathways and contribute to disease progression (Liu2012Gene).

## Structure
The BAD protein, a pro-apoptotic member of the BCL-2 family, is characterized by its BH3 domain, which is crucial for its apoptotic activity. The primary structure of BAD includes a sequence of 204 amino acids, with a molecular weight of approximately 22 kD (Bruckheimer1998The). This sequence facilitates interactions with anti-apoptotic proteins such as BCL-2 and BCL-XL (Zha1996Serine).

In terms of secondary structure, BAD contains alpha helices, particularly within the BH3 domain, which is essential for binding to the hydrophobic groove of anti-apoptotic BCL-2 family members (Danial2007BCL2; Kluck2010Bcl2). The tertiary structure of BAD is stabilized by hydrophobic interactions, which are critical for its function and interactions with other proteins (Danial2007BCL2).

Post-translational modifications, such as phosphorylation, play a significant role in regulating BAD's activity. Phosphorylation at serine residues, specifically Ser-112 and Ser-136, affects its binding affinity and subcellular localization, switching its interaction from BCL-XL to 14-3-3 proteins, thereby modulating its pro-apoptotic function (Zha1996Serine). BAD does not typically form quaternary structures but can interact with other proteins to form complexes (Bruckheimer1998The).

## Function
The human gene BAD encodes a pro-apoptotic member of the Bcl-2 family, specifically a 'BH3 domain only' protein, which plays a crucial role in regulating apoptosis in healthy cells. BAD promotes apoptosis by interacting with anti-apoptotic proteins such as Bcl-2 and Bcl-XL, primarily through its BH3 domain. This interaction leads to the inhibition of these anti-apoptotic proteins, facilitating the release of cytochrome c from mitochondria and promoting cell death (Tan2000BAD; Reed2000Mechanisms).

In healthy cells, BAD's pro-apoptotic activity is tightly regulated by phosphorylation. Phosphorylation at specific serine residues, such as Ser-112, Ser-136, and Ser-155, inhibits BAD's ability to bind to Bcl-XL, thereby preventing apoptosis. This phosphorylation is mediated by kinases like Protein Kinase A (PKA) and Akt, which sequester BAD in the cytosol by promoting its binding to 14-3-3 proteins, thus preventing its translocation to the mitochondria (Cory2002The; Tan2000BAD).

The regulation of BAD through phosphorylation allows cells to control apoptosis in response to survival signals, maintaining cellular homeostasis and preventing unwarranted cell death (Cory2002The; Reed2000Mechanisms).

## Clinical Significance
The BAD gene, a pro-apoptotic member of the BCL-2 family, plays a crucial role in regulating apoptosis. Dysregulation of BAD, through mutations or altered interactions, can significantly impact disease progression, particularly in cancer. The Gene Interaction Enrichment and Network Analysis (GIENA) tool has identified the BAD pathway as significantly dysregulated in the context of p53 mutations, which are common in various cancers. This dysregulation is critical for understanding the phenotypic differences related to p53 status, as it affects apoptosis signaling pathways (Liu2012Gene).

In complex diseases, changes in gene interactions involving BAD, rather than expression alone, are significant in understanding disease mechanisms. The BAD gene acts as a hub in its pathway, and its interactions, such as those with CSF2RB-IL3RA and PRKACG-PRKAR2A, are crucial for maintaining molecular balance in signaling pathways. These interactions are essential for apoptosis signaling, and their dysregulation can lead to impaired apoptosis, allowing cancer cells to survive (Liu2012Gene).

Understanding the clinical significance of BAD interactions can help identify specific points of perturbation within pathways, offering potential targets for experimental testing and therapeutic intervention (Liu2012Gene).

## Interactions
The BAD protein, a pro-apoptotic member of the Bcl-2 family, is involved in critical protein-protein interactions that regulate apoptosis. BAD interacts with anti-apoptotic proteins such as Bcl-2 and Bcl-X_L, promoting apoptosis by displacing pro-apoptotic proteins like Bax or Bak. This interaction is crucial for the regulation of cell death pathways. When unphosphorylated, BAD binds to Bcl-X_L, inhibiting its anti-apoptotic function. However, upon phosphorylation by kinases such as protein kinase B (PKB/Akt), BAD's pro-apoptotic activity is inhibited. Phosphorylated BAD is recognized and bound by 14-3-3 proteins, which sequester it away from Bcl-X_L, thereby preventing it from promoting apoptosis (Pawson2000Protein–protein).

The phosphorylation of BAD is a key regulatory mechanism, with kinases like Akt playing a significant role in this process. Akt phosphorylates BAD, leading to its inactivation and subsequent binding by 14-3-3 proteins. This interaction highlights the dynamic regulation of BAD's pro-apoptotic function through phosphorylation-dependent protein-protein interactions, which are essential for maintaining cellular homeostasis and preventing unwarranted cell death (Pawson2000Protein–protein).


## References


[1. (Danial2007BCL2) Nika N. Danial. Bcl-2 family proteins: critical checkpoints of apoptotic cell death. Clinical Cancer Research, 13(24):7254–7263, December 2007. URL: http://dx.doi.org/10.1158/1078-0432.CCR-07-1598, doi:10.1158/1078-0432.ccr-07-1598. This article has 612 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.CCR-07-1598)

[2. (Tan2000BAD) Yi Tan, Matthew R. Demeter, Hong Ruan, and Michael J. Comb. Bad ser-155 phosphorylation regulates bad/bcl-xl interaction and cell survival. Journal of Biological Chemistry, 275(33):25865–25869, August 2000. URL: http://dx.doi.org/10.1074/jbc.m004199200, doi:10.1074/jbc.m004199200. This article has 256 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m004199200)

[3. (Pawson2000Protein–protein) Tony Pawson and Piers Nash. Protein–protein interactions define specificity in signal transduction. Genes &amp; Development, 14(9):1027–1047, May 2000. URL: http://dx.doi.org/10.1101/gad.14.9.1027, doi:10.1101/gad.14.9.1027. This article has 571 citations.](https://doi.org/10.1101/gad.14.9.1027)

[4. (Bruckheimer1998The) E. M. Bruckheimer, S. H. Cho, M. Sarkiss, J. Herrmann, and T. J. McDonnell. The Bcl-2 gene family and apoptosis, pages 75–105. Springer Berlin Heidelberg, 1998. URL: http://dx.doi.org/10.1007/bfb0102306, doi:10.1007/bfb0102306. This article has 22 citations.](https://doi.org/10.1007/bfb0102306)

[5. (Zha1996Serine) Jiping Zha, Hisashi Harada, Elizabeth Yang, Jennifer Jockel, and Stanley J Korsmeyer. Serine phosphorylation of death agonist bad in response to survival factor results in binding to 14-3-3 not bcl-xl. Cell, 87(4):619–628, November 1996. URL: http://dx.doi.org/10.1016/s0092-8674(00)81382-3, doi:10.1016/s0092-8674(00)81382-3. This article has 2038 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(00)81382-3)

[6. (Cory2002The) Suzanne Cory and Jerry M. Adams. The bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer, 2(9):647–656, September 2002. URL: http://dx.doi.org/10.1038/nrc883, doi:10.1038/nrc883. This article has 3033 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrc883)

[7. (Kluck2010Bcl2) Ruth Kluck. Bcl-2 family-regulated apoptosis in health and disease. Cell Health and Cytoskeleton, pages 9, April 2010. URL: http://dx.doi.org/10.2147/CHC.S6228, doi:10.2147/chc.s6228. This article has 110 citations.](https://doi.org/10.2147/CHC.S6228)

[8. (Liu2012Gene) Yu Liu, Mehmet Koyutürk, Jill S Barnholtz-Sloan, and Mark R Chance. Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases. BMC Systems Biology, June 2012. URL: http://dx.doi.org/10.1186/1752-0509-6-65, doi:10.1186/1752-0509-6-65. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1752-0509-6-65)

[9. (Reed2000Mechanisms) John C. Reed. Mechanisms of apoptosis. The American Journal of Pathology, 157(5):1415–1430, November 2000. URL: http://dx.doi.org/10.1016/s0002-9440(10)64779-7, doi:10.1016/s0002-9440(10)64779-7. This article has 936 citations.](https://doi.org/10.1016/s0002-9440(10)64779-7)